Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals

Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 ((177)Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine. Since the first market authorization in 2018 of [¹⁷⁷Lu]Lu-DOTATATE (Lutathera®) ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladrière, Typhanie, Faudemer, Julie, Levigoureux, Elise, Peyronnet, Damien, Desmonts, Cédric, Vigne, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145759/
https://www.ncbi.nlm.nih.gov/pubmed/37111725
http://dx.doi.org/10.3390/pharmaceutics15041240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145759/
https://www.ncbi.nlm.nih.gov/pubmed/37111725
http://dx.doi.org/10.3390/pharmaceutics15041240

Ejemplares similares